Amoxicillin
- Generic Name
- Amoxicillin
- Brand Names
- Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5S
- CAS Number
- 26787-78-0
- Unique Ingredient Identifier
- 9EM05410Q9
- Background
Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
- Indication
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.
Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
- Associated Therapies
- -
Comparison Between Two Different Antibiotic Regimens for the Placement of Dental Implants
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Université de Montréal
- Target Recruit Count
- 42
- Registration Number
- NCT01851681
- Locations
- 🇨🇦
Université de Montréal - Faculty of Dentistry - Dental clinics, Montreal, Quebec, Canada
Antibiotic Prophylaxis - Amoxicillin
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Bodil Lund
- Target Recruit Count
- 29
- Registration Number
- NCT01829529
- Locations
- 🇸🇪
Karolinska University Hospital. Department of Dental Medicine, Stockholm, Huddinge, Sweden
Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 96
- Registration Number
- NCT01820026
- Locations
- 🇮🇹
Manuela Merli, Rome, Italy
Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 648
- Registration Number
- NCT01792700
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 200
- Registration Number
- NCT01742429
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, Shanghai, China
Empirical Rescue Therapies of Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 424
- Registration Number
- NCT01668927
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 180
- Registration Number
- NCT01667575
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai, China
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 161
- Registration Number
- NCT01667718
- Locations
- 🇨🇳
Shanghai Jiao-Tong University School of Medicine Renji Hospital, Shanghai, Shanghai, China
Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water
- Conditions
- Interventions
- First Posted Date
- 2012-07-09
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 12
- Registration Number
- NCT01635608
- Locations
- 🇩🇪
Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Meckleburg-Vorpommern, Germany
The Effect of Routine Antibiotic Use in the Outpatient Treatment of Severely Malnourished Children Without Complications
- Conditions
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Epicentre
- Target Recruit Count
- 2412
- Registration Number
- NCT01613547
- Locations
- 🇳🇪
Centres de Récupération et d'Education Nutritionnelle Ambulatoires de Dan Issa, Madarounfa, and Gabi, Maradi, Niger
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.